Immunocompromised patients with protracted COVID-19: a review of “Long Persisters”
Abstract Purpose of Review Certain immunocompromised individuals are at risk for
protracted COVID-19, in which SARS-CoV-2 leads to a chronic viral infection. However, the …
protracted COVID-19, in which SARS-CoV-2 leads to a chronic viral infection. However, the …
Persistent COVID-19 in Immunocompromised Patients–Israeli Society of Infectious Diseases Consensus Statement on Diagnosis and Management
SE Meijer, Y Paran, A Belkin, R Ben-Ami, Y Maor… - Clinical Microbiology …, 2024 - Elsevier
Background Immunocompromised patients with impaired humoral immunity are at risk for
persistent COVID-19 (pCOVID), a protracted symptomatic disease with active viral …
persistent COVID-19 (pCOVID), a protracted symptomatic disease with active viral …
Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State
A Libra, N Ciancio, G Sambataro, E Sciacca… - Viruses, 2023 - mdpi.com
Remdesivir is one of the most attractive options for patients with hypoxemic respiratory
failure due to coronavirus disease 2019 (COVID-19). The aim of our study was to evaluate …
failure due to coronavirus disease 2019 (COVID-19). The aim of our study was to evaluate …
COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic
I Hus, A Szymczyk, J Mańko, J Drozd-Sokołowska - Biology, 2023 - mdpi.com
Simple Summary The COVID-19 pandemic significantly affected the clinical outcomes and
management of patients with hematological malignancies, who are especially vulnerable to …
management of patients with hematological malignancies, who are especially vulnerable to …
[HTML][HTML] A nationwide cross-sectional study using a web-based questionnaire survey of the duration of isolation of COVID-19 inpatients with cancer at Japanese …
N Itoh, N Akazawa, H Kurai, I Kawamura… - Journal of Infection and …, 2023 - Elsevier
There is no clear consensus regarding the optimal isolation duration for
immunocompromised patients with coronavirus disease 2019 (COVID-19). Therefore, we …
immunocompromised patients with coronavirus disease 2019 (COVID-19). Therefore, we …
Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study
E Leegwater, L Dol, MR Benard, EE Roelofsen… - Infectious Diseases and …, 2023 - Springer
Introduction Remdesivir is a registered treatment for hospitalised patients with COVID-19
that has moderate clinical effectiveness. Anecdotally, some patients' respiratory insufficiency …
that has moderate clinical effectiveness. Anecdotally, some patients' respiratory insufficiency …
[HTML][HTML] Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant …
S Jung, Y Yagi, K Fukushima, Y Nishikawa, M Tanaka… - IDCases, 2023 - Elsevier
Prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma is
characterized by repeated cycles of remission followed by symptom recurrence, persistent …
characterized by repeated cycles of remission followed by symptom recurrence, persistent …
[PDF][PDF] Ma nko, J.; Drozd-Sokołowska, J. COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic. Biology 2023 …
I Hus, A Szymczyk - 2023 - ppm.wum.edu.pl
The COVID-19 pandemic is undoubtedly the most difficult health challenge of the 21st
century with more than 600 million laboratory-confirmed SARS-CoV-2 infections and over …
century with more than 600 million laboratory-confirmed SARS-CoV-2 infections and over …
[PDF][PDF] an der,… Nieuwkoop, C. an.(2023)
E Leegwater, L Dol, MR Benard… - Rapid response to … - scholarlypublications …
Introduction: Remdesivir is a registered treatment for hospitalised patients with COVID-19
that has moderate clinical effectiveness. Anecdotally, some patients' respiratory insufficiency …
that has moderate clinical effectiveness. Anecdotally, some patients' respiratory insufficiency …
Antineoplastics/ciprofloxacin/vancomycin
M Kajova - Reactions, 1909 - ncbi.nlm.nih.gov
The woman presented to hospital on the day of onset of fever. A nasopharyngeal swab
sample tested positive for SARS-CoV-2 and sequencing revealed the B. 1.1. 7 variant. She …
sample tested positive for SARS-CoV-2 and sequencing revealed the B. 1.1. 7 variant. She …